Valencia

• Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended recruitment
  2023-504040-34-01 5 2024-11-12 Crohn’s Disease
• Apremilast study in children with active oral ulcers associated with Behçet's Disease Ended recruitment
  2023-503436-40-00 5 2024-11-11 Behcet's disease
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil … Ended recruitment
  2023-510342-24-00 5 2024-11-11 Acne vulgaris
• Sasanlimab Treatment As Bladder-Sparing Strategy For Patients With Muscle Invasive Bladder Cancer Ended recruitment
  2024-511358-36-00 4 2024-11-11 Molecularly Categorized Muscle Invasive Bladder Cancer
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- … Ended recruitment
  2024-513540-29-00 5 2024-11-07 Breast Cancer
• A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec … Ended recruitment
  2023-505617-24-00 4 2024-11-05 Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
• GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failu … Ended recruitment
  2024-510581-17-00 4 2024-11-05 Adult subjects with New York Heart Association (NYHA) Class III conges
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended recruitment
  2023-509302-30-00 5 2024-11-04 Hypertriglyceridemia
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended recruitment
  2023-509300-14-00 5 2024-10-31 Severe hypertriglyceridemia (SHTG)
• A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr … Ended recruitment
  2024-513160-25-00 5 2024-10-30 Melanoma and Non-small-cell lung cancer
• A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Ref … Ended recruitment
  2024-516149-38-00 4 2024-10-29 Hodgkin Lymphoma
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• SPOTLIGHT 204: A Multicenter, Phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability and preliminary efficacy … Ended recruitment
  2024-511801-51-00 4 2024-10-24 Basal cell carcinoma
• A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from systemic lupus erythematosus Ended recruitment
  2024-515871-37-00 5 2024-10-24 Moderate to severe systemic lupus erythematosus
• A study organ preservation with Custodiol-N solution compared with Custodiol solution in liver trasnplantation Ended recruitment
  2024-518174-13-00 5 2024-10-24 Liver transplantation
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru … Ended recruitment
  2022-502168-19-00 4 2024-10-22 chronic graft-versus-host disease
• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative … Ended recruitment
  2024-511796-15-00 5 2024-10-16 Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
• Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended recruitment
  2023-503383-17-01 5 2024-10-10 Female androgenetic alopecia
• A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho … Ended recruitment
  2024-511304-16-00 4 2024-10-10 Newly Diagnosed Advanced Stage Follicular Lymphoma
• Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoe … Ended recruitment
  2024-517782-16-00 4 2024-10-10 Colorectal cancer and metastatic disease limited to the liver with bad
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• POST-SURGICAL LIQUID BIOPSY - GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE PEGASUS STUDY Ended recruitment
  2024-517704-10-00 4 2024-09-30 Colon cancer
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Ended recruitment
  2023-507655-30-00 5 2024-09-27 Obesity

Showing 961–984 of 1,853 trials